AMES, Iowa, May 29, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, announced today that Charles J. Link, Jr., M.D., NewLink's Founder and Chief Executive Officer, is scheduled to present at the Jefferies 2013 Healthcare Conference in New York on Wednesday, June 5, 2013 at 1:00 p.m. ET. Interested parties may access a live webcast of the presentation by visiting the NewLink website at www.linkp.com. The webcast will be archived on the NewLink website following the event.
About NewLink Genetics Corporation
NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve treatment options for patients with cancer. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. For more information please visit http://www.linkp.com. Patient information is available at http://www.pancreaticcancer-clinicaltrials.com.
Gordon Link Chief Financial Officer 515-598-2925 email@example.com
SOURCE NewLink Genetics Corporation